Inventor · disambiguated record
Matthias Klinger
Also filed as: KLINGER MATTHIAS
10 granted patents·18 pending applications·131 citations·filing 2006–2025
89Inventor score
Top patents by PatentIndex Score
28 records- 0196US8007796B2Means and methods for the treatment of tumorous diseasesMICROMET AG·Filed 2006·Granted Aug 30, 2011·69 cites·18 claims
- 0295US11472886B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Oct 18, 2022·3 cites·13 claims
- 0390US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 0490US9587036B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyKUFER PETER·Filed 2011·Granted Mar 7, 2017·24 cites·34 claims
- 0589US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 0688US11987633B2Cross-species-specific single domain bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted May 21, 2024·1 cites·27 claims
- 0785US10981998B2Cross-species-specific single domain bispecific single chain antibodyKUFER PETER·Filed 2009·Granted Apr 20, 2021·5 cites·18 claims
- 0880US11154617B2Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemiaBAEUERLE PATRICK·Filed 2011·Granted Oct 26, 2021·4 cites·10 claims
- 0978US9486475B2PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 8, 2016·4 cites·14 claims
- 1075US12281172B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Apr 22, 2025·0 cites·18 claims
- 1175US2025333535A1Bispecific single chain antibody construct with enhanced tissue distributionAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 1274US2025163179A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYAMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 1369US2022088196A1Means and Methods for Treating Tumorous DiseasesAMGEN RES MUNICH GMBH·Filed 2021·Application pending·0 cites
- 1467US2011293619A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYKUFER PETER·Filed 2009·Application pending·0 cites
- 1564US2020095319A1Cross-species-specific bispecific bindersAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 1664US2023357444A1Cross-species-specific binding domainAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 1763US2010183615A1Cross-species-specific bispecific bindersMICROMET AG·Filed 2008·Application pending·0 cites
- 1861US2020362039A1Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 1961US2019169310A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYAMGEN RES MUNICH GMBH·Filed 2018·Application pending·0 cites
- 2061US2025282869A1Heteromultimer binding dll3 and cd3AMGEN INC·Filed 2023·Application pending·0 cites
- 2159US2012034228A1CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYKUFER PETER·Filed 2009·Application pending·0 cites
- 2256US2012244162A1Cross-species-specific bispecific bindersKUFER PETER·Filed 2012·Application pending·0 cites
- 2355US2024209078A1Multitargeting bispecific antigen-binding molecules of increased selectivityAMGEN INC·Filed 2021·Application pending·0 cites
- 2453US2023406929A1Polypeptide constructs binding to cd3AMGEN INC·Filed 2021·Application pending·0 cites
- 2553US2016152707A1Cross-species-specific bispecific bindersAMGEN RES MUNICH GMBH·Filed 2015·Application pending·0 cites
- 2649US2010150918A1Cross-species-specific binding domainMICROMET AG·Filed 2008·Application pending·0 cites
- 2747US2022403035A1Multitargeting antigen-binding molecules for use in proliferative diseasesAMGEN RES MUNICH GMBH·Filed 2020·Application pending·0 cites
- 2841US2017275373A1Bispecific single chain antibody construct with enhanced tissue distributionAMGEN RES MUNICH GMBH·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthias Klinger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →